Abstract
We evaluated the rate and extent of the systemic absorption of moxalactam given intraperitoneally to patients with peritonitis and end-stage renal disease who were being maintained on continuous ambulatory peritoneal dialysis. Moxalactam was administered at a concentration of 200 mg per 2-liter dialysate for the first dose, followed by 60 mg per 2-liter exchange for 23 1-h exchanges. Moxalactam concentrations in serum (mean +/- standard deviation) were 2.5 +/- 0.9 mg/liter after the first hourly dialysis, increasing to 10.3 +/- 4.8 mg/liter after 24 h of drug administration. Moxalactam levels in serum at 1 h were above the minimal inhibitory concentrations for most gram-negative organisms except Pseudomonas aeruginosa. No adverse effects of the drug were observed.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Diven W. F., Obermeyer B. D., Wolen R. L., Yu V. L., Lyon J., Zuravleff J. Measurement of serum and tissue concentration of moxalactam using high pressure liquid chromatography. Ther Drug Monit. 1981;3(3):291–295. doi: 10.1097/00007691-198103000-00011. [DOI] [PubMed] [Google Scholar]
- Kaye D., Wenger N., Agarwal B. Pharmacology of intraperitoneal cefazolin in patients undergoing peritoneal dialysis. Antimicrob Agents Chemother. 1978 Sep;14(3):318–321. doi: 10.1128/aac.14.3.318. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Popovich R. P., Moncrief J. W., Nolph K. D., Ghods A. J., Twardowski Z. J., Pyle W. K. Continuous ambulatory peritoneal dialysis. Ann Intern Med. 1978 Apr;88(4):449–456. doi: 10.7326/0003-4819-88-4-449. [DOI] [PubMed] [Google Scholar]
- Wise R., Baker S., Livingston R. Comparison of cefotaxime and moxalactam pharmacokinetics and tissue levels. Antimicrob Agents Chemother. 1980 Sep;18(3):369–371. doi: 10.1128/aac.18.3.369. [DOI] [PMC free article] [PubMed] [Google Scholar]